PHILADELPHIA—Adequate doses of calcifediol can correct 25-hydroxyvitamin D deficiency and improve malnutrition-inflammation status in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT), researchers reported at Kidney Week 2011.
PHILADELPHIA—Cinacalcet plus low-dose vitamin D provides a more effective approach to treating secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients, according to findings presented at Kidney Week 2011.
PHILADELPHIA—Uncontrolled secondary hyperparathyroidism (SHPT) has been on the increase among black hemodialysis (HD) patients since the recent implementation of the federal government’s prospective payment system for dialysis services, researchers reported at Kidney Week 2011.
PHILADELPHIA—Untreated secondary hyperparathyroidism (SHPT) is associated with increased mortality risk in hemodialysis (HD) patients, according to a report presented at Kidney Week 2011.
PHILADELPHIA—Serum phosphorus levels in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT) decrease during treatment with cinacalcet, data presented at Kidney Week 2011 show. This effect occurs regardless of baseline SHPT severity.
PHILADELPHIA—Alfacalcidol and paricalcitol have similar efficacy in suppressing secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients researchers reported at Kidney Week 2011.
PHILADELPHIA—Cholecalciferol with or without doxercalciferol may be an appropriate treatment for secondary hyperparathyroidism (SHPT) in kidney transplant recipients, according to the findings of a small study presented at Kidney Week 2011.
PHILADELPHIA—Elevated levels of serum parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF-23) are associated with an increased likelihood of progression of vascular calcification (VC) in hemodialysis patients, French researchers reported at Kidney Week 2011.
PHILADELPHIA—The dose of cinacalcet dialysis patients receive prior to renal transplantation and their time on dialysis appear to be the most important factors associated with reintroduction of the drug during the first year following transplantation, Spanish researchers reported at Kidney Week 2011.
Please login or register first to view this content.
